ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 199 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $291,000 | -7.0% | 6,601 | +4.1% | 0.00% | – |
| Q1 2021 | $313,000 | +17.2% | 6,343 | 0.0% | 0.00% | – |
| Q4 2020 | $267,000 | -9.5% | 6,343 | -1.6% | 0.00% | – |
| Q3 2020 | $295,000 | -35.6% | 6,443 | -29.4% | 0.00% | – |
| Q2 2020 | $458,000 | -26.5% | 9,129 | -24.7% | 0.00% | -100.0% |
| Q1 2020 | $623,000 | -16.6% | 12,121 | +0.2% | 0.00% | 0.0% |
| Q4 2019 | $747,000 | +2.9% | 12,092 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $726,000 | -28.8% | 12,092 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,020,000 | -50.0% | 12,092 | -50.7% | 0.00% | 0.0% |
| Q1 2019 | $2,039,000 | +135.7% | 24,503 | +100.6% | 0.00% | 0.0% |
| Q4 2018 | $865,000 | -17.1% | 12,214 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $1,044,000 | -38.7% | 12,214 | -16.8% | 0.00% | -50.0% |
| Q2 2018 | $1,702,000 | +6.8% | 14,683 | -25.5% | 0.00% | 0.0% |
| Q1 2018 | $1,594,000 | – | 19,697 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
| Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
| ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
| Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
| Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
| Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |